Oculus Innovative Sciences, Inc. Appoints Jay E. Birnbaum to Its Board of Directors
PETALUMA, Calif.--(BUSINESS WIRE)--
Oculus Innovative Sciences, Inc. (NASDAQ:OCLS) announced today the appointment of Jay E. Birnbaum, Ph.D., to its board of directors. Dr. Birnbaum is a pharmacologist and previous to his current role as a consultant to pharmaceutical companies, he served as vice president of global project management at Novartis/Sandoz Pharmaceuticals Corporation, where he had responsibility for strategic planning and development of the company's dermatology portfolio. In this position, he directed clinical programs and NDA submissions on products including terbinafine (Lamisil(R)) and cyclosporine (Neoral/Sandimmune(R)). He headed a number of corporate initiatives dealing with the standardization and quality of clinical trials and was chairman of Organogenesis/Novartis joint development committee during the development and registration of Apilgraf(R).
Dr. Birnbaum is a co-founder of Kythera Biopharmaceuticals, a company developing products in aesthetic and restorative dermatology, as well as a member of NanoBio Corporation's scientific advisory board.
"I am pleased to welcome Dr. Jay Birnbaum to Oculus' board of directors," stated Hoji Alimi, chief executive officer, president, and chairman of the board of Oculus. "He brings the scientific and formulation background as well the FDA regulatory understanding, which is most valuable as we focus on ongoing U.S. clinical trials to validate our Microcyn(R) Technology for a variety of wound care and anti-infective indications."
About Oculus
Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures and markets a family of Microcyn Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating, oxychlorine compound that is designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, as well as viruses, fungi and spores.
Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.
Oculus, Microcyn(R), and Dermacyn(R) are trademarks or registered trademarks of Oculus Innovative Sciences, Inc. All other trademarks and services marks are the property of their respective owners.
Source: Oculus Innovative Sciences, Inc.
Released April 25, 2007